About this trial
The goal of the DC Cohort is to establish a clinic-based city-wide longitudinal cohort that will describe clinical outcomes, and improve the quality of care for patients diagnosed with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) or at higher risk for acquiring HIV and receiving care in Washington, DC.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patient is receiving care for HIV at one or more of the twelve participating clinics in the DC Cohort.
Patient is either age 18 years or older, or seeks HIV care independently and is able to understand and sign informed consent.
Patient is a minor who is consented by a parent or legal guardian.
Disqualifiers
Patient is unable or refuses to provide informed consent.
Minor children ages 12 through 17 who are unaware of their HIV status
PrEP (e.g., TDF/FTC, Descovy, Apretude)
Combination ART indicative of nPEP in an HIV-uninfected person
Trial population
Study participants will include men, women and children receiving HIV prevention, care or treatment services at major publicly-funded, government and academic medical centers in the District of Columbia.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
viral suppression among persons with HIV
The study will assess rates of viral suppression (defined as an HIV RNA test less than 200 copies/ml) from enrollment to 10 years post enrollment.
clinical outcomes persons at higher risk for acquiring HIV
Persons who are receiving HIV preventive services will be followed longitudinally to assess time to HIV positivity from baseline to 5 years post enrollment
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
George Washington University
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator